Mucopolysaccharidoses Differential Diagnosis by Mass Spectrometry-Based Analysis of Urine Free Glycosaminoglycans—A Diagnostic Prediction Model
Biomolecules · 2023
DOI: 10.3390/biom13030532 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Francesca D'Avanzo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Diagnosis and Therapy of Lysosomal Disorders, Department of Women's and Children's Health, University of Padova, 35128 Padova, Italy. Hauptthemen laut MEDLINE: Glycosaminoglycans, Mucopolysaccharidoses. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Elypta AB.
Abstract (Originalsprache)
Impaired glycosaminoglycans (GAGs) catabolism may lead to a cluster of rare metabolic and genetic disorders called mucopolysaccharidoses (MPSs). Each subtype is caused by the deficiency of one of the lysosomal hydrolases normally degrading GAGs. Affected tissues accumulate undegraded GAGs in cell lysosomes and in the extracellular matrix, thus leading to the MPS complex clinical phenotype. Although each MPS may present with recognizable signs and symptoms, these may often overlap between subtypes, rendering the diagnosis difficult and delayed. Here, we performed an exploratory analysis to develop a model that predicts MPS subtypes based on UHPLC-MS/MS measurement of a urine free GAG profile (or GAGome). We analyzed the GAGome of 78 subjects (38 MPS, 37 healthy and 3 with other MPS symptom-overlapping disorders) using a standardized kit in a central-blinded laboratory. We observed several MPS subtype-specific GAGome changes. We developed a multivariable penalized Lasso logistic regression model that attained 91.2% balanced accuracy to distinguish MPS type II vs. III vs. any other subtype vs. not MPS, with sensitivity and specificity ranging from 73.3% to 91.7% and from 98.4% to 100%, depending on the predicted subtype. In conclusion, the urine GAGome was revealed to be useful in accurately discriminating the different MPS subtypes with a single UHPLC-MS/MS run and could serve as a reliable diagnostic test for a more rapid MPS biochemical diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Diagnosis and Therapy of Lysosomal Disorders, Department of Women's and Children's Health, University of Padova, 35128 Padova, Italy.
- Fondazione Istituto di Ricerca Pediatrica Città della Speranza, 35127 Padova, Italy.
- Regional Coordinator Centre for Rare Diseases, University Hospital of Udine, 33100 Udine, Italy.
- Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.
- Department of Oncology-Pathology, Karolinska Institute, 171 77 Stockholm, Sweden.
ORCID-Profile: Francesca D'Avanzo, Andrea Dardis, Francesco Gatto, Rosella Tomanin
Förderung
- Elypta AB
Zitieren
APA
D'Avanzo, F., Zanetti, A., Dardis, A., Scarpa, M., Volpi, N., Gatto, F., & Tomanin, R. (2023). Mucopolysaccharidoses Differential Diagnosis by Mass Spectrometry-Based Analysis of Urine Free Glycosaminoglycans—A Diagnostic Prediction Model. Biomolecules. https://doi.org/10.3390/biom13030532
Vancouver
D'Avanzo F, Zanetti A, Dardis A, Scarpa M, Volpi N, Gatto F, et al. Mucopolysaccharidoses Differential Diagnosis by Mass Spectrometry-Based Analysis of Urine Free Glycosaminoglycans—A Diagnostic Prediction Model. Biomolecules. 2023. doi:10.3390/biom13030532
BibTeX
@article{DAvanzo2023,
author = {D'Avanzo, Francesca and Zanetti, Alessandra and Dardis, Andrea and Scarpa, Maurizio and Volpi, Nicola and Gatto, Francesco and Tomanin, Rosella},
title = {Mucopolysaccharidoses Differential Diagnosis by Mass Spectrometry-Based Analysis of Urine Free Glycosaminoglycans—A Diagnostic Prediction Model},
journal = {Biomolecules},
year = {2023},
doi = {10.3390/biom13030532}
}
EUVIMED